BUSINESSPUBLIC Enveric bets on trip-free mental health drug for FDA approval hopes [Green Market Report]
Tuesday, June 25, 2024 1 min read
Key Takeaway: Enveric Biosciences is prioritizing the development of EB-003, a new compound aimed at treating mental health disorders without causing hallucinations. The drug is designed to enhance neuroplasticity, distinguishing it from traditional psychedelic treatments. The company plans to hold a pre-IND meeting with the FDA in early 2025 to discuss its progress.
Price reaction · baseline $120.42 (2024-06-24 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close · peak
-7.3%
day 1
-4.4%
day 3
-6.4%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric is focusing on a novel treatment for mental health disorders.
EB-003 aims to promote neuroplasticity without hallucinogenic effects.
The company is advancing its pre-clinical development.
Full Press Release Details
Biotechnology company Enveric Biosciences (NASDAQ: ENVB) said it is prioritizing the development of EB-003, a compound designed to treat mental health disorders without hallucinogenic effects. The company said EB-003 is intended to promote neuroplasticity while avoiding the hallucinations associated with some psychedelic-based treatments. Enveric is advancing pre-clinical development and aims for a pre-IND meeting with the FDA in early 2025, the company announced Tuesday.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a compound developed by Enveric to treat mental health disorders without causing hallucinations.
What are the goals of EB-003?
The primary goal of EB-003 is to promote neuroplasticity while avoiding hallucinogenic effects.
When does Enveric plan to meet with the FDA?
Enveric aims to hold a pre-IND meeting with the FDA in early 2025.
What stage is EB-003 in development?
EB-003 is currently in the pre-clinical development stage.